ReCode Therapeutics har publicerat resultat från mRNA-studier gällande PCD med mutation i DNAI1. Detta framsteg är lovande inför framtiden.
Utdrag ur pressmeddelandet:
”Data from ReCode’s RCT1100-103 Phase 1b trial across sites in Denmark, Germany, and the United States showed that 57% of patients achieved meaningful improvement in mucociliary clearance at 12 weeks. Bronchoscopy confirmed restoration of protein and ciliary activity in the airway. Restoration of protein was correlated with positive changes in mucociliary clearance. The drug was safe and well-tolerated. There were no serious adverse events.”
Läs mer här: https://recodetx.com/recode-therapeutics-achieves-a-first-proof-of-activity-in-primary-ciliary-dyskinesia-patients/







